For American biochemist Jennifer DouDNA, 2020 is undoubtedly an unforgettable milestone.

That year, she stood on the Nobel Prize in Chemistry podium for co developing CRISPR-Cas9 gene editing technology. Subsequently, Caribou Biosciences, which she co founded, stood at the center of the wave of cell therapy, carrying the expectation of bringing gene editing from the laboratory to the bedside.

Unexpectedly, six years later, this biotech with its own star aura is closing down and its stock price is plummeting.

The trigger came from the setback in research and development progress. Although Caribou still has $114 million in cash on its account, it cannot raise the funds needed for the Phase III trial. When capital collectively withdraws from allogeneic CAR-T and shifts towards in vivo therapies, and when autologous CAR-T continues to improve and compress the survival space of "spot type" therapies, even the Nobel Prize halo cannot bridge the gap between scientific vision and capital reality.

The shutdown of Caribou is not just a company failure, it marks a collective retreat from what was once seen as the main race track for next-generation cell therapy. CEO Rachel Haurwitz wrote on LinkedIn: "Today, Caribou's story has taken a heartbreaking turn. ”

The audience for this statement is far beyond Caribou's shareholders.

01. "Parabola"

In August 2017, the FDA approved the launch of the first CAR-T cell therapy, ushering humanity into the era of cell therapy.

For a long time after this, CAR-T therapies that have been launched all use patients' own T cells, with the advantage of being able to function in the body for a long time without rejection. But the limitations are also prominent: autologous therapy takes a long time and acute leukemia patients cannot afford to wait; Many critically ill patients have insufficient T cells and are difficult to engineer.

Therefore, allogeneic cell therapy has become an important direction. Heterogeneous cell sources are more diverse, including peripheral blood, umbilical cord blood, and induced pluripotent stem cells, making them easier to mass produce and less time-consuming.

Caribou is a representative of this direction.

In 2011, Caribou was spun off from DouDNA Laboratory and dedicated to developing the next generation of "spot type" CAR-T and CAR-NK therapies through CRISPR gene editing to address the host immune system's rejection of allogeneic cells.

Capital once responded with great enthusiasm. In 2016, Caribou completed a $30 million Series B financing supported by Novartis. In March 2021, AbbVie participated in the company's $115 million Series C financing round; Previously, AbbVie also paid $40 million to collaborate with them to advance two CRISPR edited cell therapies. Pfizer also expressed confidence in Caribou technology with a $25 million equity investment in 2023.

In July 2021, Caribou issued 19 million shares at $16 per share, raising approximately $304 million, making it one of the largest IPOs in the gene editing field at the time. The stock price hit $32.65 in September of that year.

The financing mentioned above is supported by Caribou's unique chRDNA gene editing platform. This technology achieves higher accuracy and lower off target rate than traditional CRISPR-Cas9 by incorporating DNA bases into guide RNA, and supports multiple gene knockout and insertion.

The company has pushed three allogeneic CAR-T drugs to the clinical stage: CB-010 targeting CD19 for relapsed refractory B-cell non Hodgkin lymphoma and lupus nephritis; CB-011 targets BCMA for multiple myeloma; CB-012 targets CLL-1 for acute myeloid leukemia.

Taking CB-010 (visa cel) as an example, this therapy underwent triple gene editing: CD19 CAR site-specific knockout was performed on the TRAC locus, while TRAC was knocked out to clear T cell receptors and reduce the risk of graft-versus-host disease; And knocking out the PD-1 gene to enhance the sustained anti-tumor activity of CAR-T cells.

In the Phase I ANTLER trial, the confirmatory cohort achieved an overall response rate of 82%, a complete response rate of 64%, and a progression free survival rate of 51% at 12 months for patients with second-line large B-cell lymphoma; The total remission rate in the optimized queue is 86%, the complete remission rate is 63%, and the 12-month progression free survival rate is 53%. The FDA has granted advanced therapy recognition for visco cel regenerative medicine and has reached an agreement with the company on the phase III trial design.

CB-011 also performed well in the Phase I CaMMouflage trial for relapsed or refractory multiple myeloma (r/r MM), with a recommended overall response rate of 92% and a complete response rate of 83% for BCMA initial treatment patients at extended doses, and 91% of assessable patients achieving negative minimal residual lesions.
But a parabolic turn occurred in 2024.

In March of that year, Caribou suspended CB-020, an iPSC derived allogeneic anti-ROR1 CAR-NK cell therapy for solid tumors; By July, the company had completely abandoned NK cell therapy and laid off 21 preclinical CAR-NK cell therapy researchers, accounting for 12% of the company's total personnel.

With the complete abandonment of NK cell therapy, Caribou has focused its resources on the allogeneic CAR-T platform. At that time, the company's stock price had continued to decline, with a market value of only $217 million, a drop of over 90% from nearly $3 billion in September 2021. In 2025, the company will further abandon the field of autoimmune diseases and lay off employees again.

On October 6, 2026, Caribou announced the cessation of all clinical development of Visa Cell and CB-011, implemented significant layoffs, and initiated a strategic evaluation to consider mergers, acquisitions, business combinations, or asset sales.

Caribou Biosciences stock price trend chart

02. Misalignment dilemma

With over $100 million in cash and FDA approved Phase III design, these conditions would have been sufficient five years ago for a biotech company to continue operating. Caribou was unable to achieve it.

In the first half of 2026, the total amount of mergers and acquisitions and financing in the CGT field exceeded 16.6 billion US dollars, but the funds were highly concentrated in emerging directions such as CAR-T in vivo. In the 12 months before and after Caribou announced its shutdown, major global pharmaceutical companies paid over $18 billion for in vivo CAR-T technology.

Lilly acquires Kelonia Therapeutics for up to $7 billion, with $3.25 billion as a down payment. Johnson&Johnson has reached a partnership with Sail Biomedicines for a down payment of $785 million and has obtained the exclusive option to acquire Sail for $2.58 billion. AbbVie acquires Capstan Therapeutics for $2.1 billion, BMS acquires Orbital Therapeutics for $1.5 billion, and AstraZeneca acquires EsoBiotec for $1 billion.

Investors are willing to pay a high premium for the concept of "in vivo manufacturing CAR-T", but have not provided funding for the Phase III validation of allogeneic CAR-T.
At the same time, the continuous improvement of autologous CAR-T is compressing the survival space of allogeneic therapies. Kite has reduced Yescarta's production turnaround time from 16 days to 14 days and plans to increase cell therapy production fourfold by 2026. The core selling point of allogeneic therapy, which is "spot supply and time-saving", has therefore been weakened.

A more profound change comes from in vivo CAR-T technology, which bypasses all aspects of in vitro manufacturing, cold chain transportation, and reinfusion, delivering CAR genes directly to T cells in patients through nanoparticles or viral vectors.

The statement made by Cindy Peretti, Executive Vice President of Kite, is quite representative: the company is fully betting on in vivo therapies because we have not yet seen allogeneic therapies achieve the deep, long-lasting, and widespread response of autologous therapies in oncology.

This dilemma is not unique to Caribou.

Cellectis, a French company that was once one of the representative companies of allogeneic CAR-T, terminated all two allogeneic pipelines in September 2026 and switched to in vivo gene editing. On the same day, its stock price plummeted by 40.97%, and its market value shrank by more than 95% compared to its IPO in 2015.
AvenCell CEO Andrew Schiermeier described the current environment as a 'nuclear winter', where 'the only thing that can save us is data'.

The competitive landscape is also intensifying the difficulty of financing.

Allogeneic companies generally compete head-on with autologous CAR-T, targeting indications already covered by mature autologous therapies. Leerink analysts pointed out that these "old established" foreign companies are still improving their already successful areas, which is "difficult to excite". The 'home run' of allogeneic therapy should be something that autologous therapy cannot achieve, but most companies have not found such a differentiated positioning.

It is worth noting that the "highlight data" of allogeneic studies are still based on small samples of tens to tens of cases, while autologous controls are registration level evidence of hundreds of cases followed up for five years. Whether small sample data can be reproduced in Phase III trials is an unavoidable concern for investors.

Looking back at Caribou, multiple strategic contractions have already laid the groundwork. Each contraction reinforces the negative narrative of 'cash consumption and uncertain milestones', ultimately leading to a collapse of trust in the capital market.

03. After the shutdown

After the strategic review was initiated, Caribou did not have many choices in front of him.

Wall Street's pursuit of the "shell" has provided an ironic exit for this once glorious cell therapy company. This business revolves around "reverse merger", which involves the merger of private companies and listed companies to quickly enter markets such as NASDAQ.

Caribou meets multiple criteria: being listed on NASDAQ is more attractive to private drug developers than the over-the-counter market; At the end of the second quarter, we had $114 million in cash, cash equivalents, and securities; Based on financial data as of June 30th and Wednesday's closing price, its negative enterprise value (EV) is estimated to be around $20 million, with Leerink estimating a maximum of $30 million.

Negative EV means that after deducting cash, the market assigns zero or even less value to its core operating business. For private developers, this is actually a bonus - they may not have to pay a high premium to acquire this listing carrier.

However, Caribou has disclosed that it has hired Wedbush Securities as its exclusive financial advisor, an arrangement that typically means a general sale or asset divestment is the preferred option.

The remaining core values of the company are concentrated in three areas: the multi editing capabilities of the chRDNA platform, the Phase I data package and FDA communication records of Visa Cell and CB-011, and the cash on the books sufficient to support operations for a period of time.

For large pharmaceutical companies with existing CAR-T layouts but lacking allogeneic platforms, these assets can save years of early development time. Caribou's historical partnership with Novartis and Pfizer may become a starting point for negotiations, but the precedent of AbbVie terminating its partnership in 2023 indicates that the patience of major pharmaceutical companies with allogeneic CAR-T is diminishing.

If the overall sale is difficult to achieve, technology licensing is the second best option.

ChRDNA supports multiple gene knock in and knockout, and the company has previously explored its use in non tumor fields such as liver targeted delivery and DNA gene knockout. Granting authorization to companies with clinical development resources can at least retain some scientific value, but the revenue is far from sufficient to support the independent operation of listed companies.

Regardless of which path, the possibility of Caribou continuing to exist as an independent entity is already very small. After all, the differentiation of allogeneic CAR-T tracks has already begun.

Allogene positions cema cel as a first-line consolidation therapy guided by minimal residual lesions, avoiding direct competition with autologous CAR-T in the second and third lines. This strategy has obtained FDA's RMAT certification and fast track qualification; The first data from the ALPHA3 randomized phase II trial was released in April 2026, and the EFS midterm analysis is expected to be read out in mid-2027. Cellectis abandoned allogeneic CAR-T and switched to in vivo gene editing.

The commonality between the two is that they no longer attempt to prove that allogeneic therapy is better in areas where autologous therapy has already been successful, but instead seek clinical scenarios that autologous therapy cannot or does not cover sufficiently.

Several domestic enterprises are laying out allogeneic CAR-T, CAR-NK, and iPSC derived cell therapies, and some pipelines have entered the clinical stage. Caribou's lesson shows that a differentiated technology platform and early clinical data alone are not sufficient to support critical registration trials. When the capital environment tightens, investors' tolerance for homogeneous competition and uncertainty will rapidly decrease.

Some industry insiders believe that if Chinese companies choose indications that compete head-on with autologous CAR-T, they may face financing difficulties similar to Caribou.

Another revelation is the importance of time windows. Caribou had ample cash and market attention when it went public in 2021, but the key Phase I data for Visa Cell was not released until 2024, during which it underwent multiple strategic adjustments. The mismatch between the speed of pipeline advancement and the pace of financing has consumed the trust of the capital market.

For domestic cell therapy companies, accelerating key milestones when capital is abundant is more important than repeatedly adjusting strategies in the cold winter.

Caribou, which emerged from the Nobel Prize winning laboratory, ultimately failed to translate the scientific halo of CRISPR into a commercially available therapy. Allogeneic cell therapy still has irreplaceable value in scenarios such as acute leukemia and multi line treatment failure patients, but the track will belong to companies that can validate more accurate hypotheses with less capital.

Caribou's story is not completely over yet, but it has already marked several paths that newcomers need to avoid. The distance between scientific leadership and commercial implementation is often longer than the road from the laboratory to the bedside.

Reference article:
1 Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate； biopharmadive
2 Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer.； biospace
3. The Nobel Prize team was founded, and the next generation cell therapy company Caribou completely abandoned CAR-NK, causing the stock price to continue to fall; Biological world
4 CAR-T biotech Caribou makes ‘heartbreaking’ call to shrink headcount, halt pipeline； fiercebiotech
5 Caribou Biosciences to Evaluate Strategic Alternatives； cariboubio
6 In the hunt for reverse merger targets, Caribou could be prized game； biopharmadive